Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review

Molecular Aspects of Medicine

Volumn 51, Issue , 2016, Pages 115-124

  Taniguchi Ikeda, Mariko ^a   Morioka, Ichiro ^a   Iijima, Kazumoto ^a   Toda, Tatsushi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antisense therapy; Fukuyama congenital muscular dystrophy; Glycosyltransferase; O Mannose glycan; Ribitol 5 phosphate; DG

Indexed keywords

ALPHA DYSTROGLYCAN; CORTICOSTEROID; DYSTROPHIN; LAMININ; MANNOSE; MINIDYSTROPHIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; DYSTROGLYCAN; GLYCOSYLTRANSFERASE;

ADENO ASSOCIATED VIRUS; ALPHA DYSTROGLYCANOPATHY; ANTISENSE THERAPY; AUTOSOMAL RECESSIVE DISORDER; CLINICAL TRIAL (TOPIC); DUCHENNE MUSCULAR DYSTROPHY; ENZYME REPLACEMENT; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE THERAPY; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB GIRDLE MUSCULAR DYSTROPHY 2I; MUSCLE EYE BRAIN DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN GLYCOSYLATION; REVIEW; WALKER WARBURG SYNDROME; CHEMISTRY; MEDICAL RESEARCH; METABOLISM;

BIOMEDICAL RESEARCH; DYSTROGLYCANS; ENZYME REPLACEMENT THERAPY; GENETIC THERAPY; GLYCOSYLTRANSFERASES; HUMANS; WALKER-WARBURG SYNDROME;

EID: 84979672144     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2016.07.003     Document Type: Review

References (99)

1. Annexstad, E.J., Lund-Petersen, I., Rasmussen, M., Duchenne muscular dystrophy. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke 134:14 (2014), 1361–1364.
2. Barresi, R., Michele, D.E., Kanagawa, M., Harper, H.A., Dovico, S.A., Satz, J.S., et al. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med 10:7 (2004), 696–703.
3. Bowe, M.A., Deyst, K.A., Leszyk, J.D., Fallon, J.R., Identification and purification of an agrin receptor from Torpedo postsynaptic membranes: a heteromeric complex related to the dystroglycans. Neuron 12:5 (1994), 1173–1180.
4. Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther 20:2 (2012), 443–455.
5. Brockington, M., Blake, D.J., Prandini, P., Brown, S.C., Torelli, S., Benson, M.A., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am. J. Hum. Genet 69:6 (2001), 1198–1209.
6. Buysse, K., Riemersma, M., Powell, G., van Reeuwijk, J., Chitayat, D., Roscioli, T., et al. Missense mutations in beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum. Mol. Genet 22:9 (2013), 1746–1754.
7. Campbell, K.P., Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80:5 (1995), 675–679.
8. Carss, K.J., Stevens, E., Foley, A.R., Cirak, S., Riemersma, M., Torelli, S., et al. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of alpha-dystroglycan. Am. J. Hum. Genet 93:1 (2013), 29–41.
9. Chiba, A., Matsumura, K., Yamada, H., Inazu, T., Shimizu, T., Kusunoki, S., et al. Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin. J. Biol. Chem 272:4 (1997), 2156–2162.
10. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:9791 (2011), 595–605.
11. Cohn, R.D., Campbell, K.P., Molecular basis of muscular dystrophies. Muscle Nerve 23:10 (2000), 1456–1471.
12. Cormand, B., Pihko, H., Bayes, M., Valanne, L., Santavuori, P., Talim, B., et al. Clinical and genetic distinction between Walker-Warburg syndrome and muscle-eye-brain disease. Neurology 56:8 (2001), 1059–1069.
13. Darin, N., Kroksmark, A.K., Ahlander, A.C., Moslemi, A.R., Oldfors, A., Tulinius, M., Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur. J. Paediatr. Neurol 11:6 (2007), 353–357.
14. D'Amico, A., Tessa, A., Bruno, C., Petrini, S., Biancheri, R., Pane, M., et al. Expanding the clinical spectrum of POMT1 phenotype. Neurology 66:10 (2006), 1564–1567 Discussion 1461.
15. Di Costanzo, S., Balasubramanian, A., Pond, H.L., Rozkalne, A., Pantaleoni, C., Saredi, S., et al. POMK mutations disrupt muscle development leading to a spectrum of neuromuscular presentations. Hum. Mol. Genet 23:21 (2014), 5781–5792.
16. Diesen, C., Saarinen, A., Pihko, H., Rosenlew, C., Cormand, B., Dobyns, W.B., et al. POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain disease. J. Med. Genet, 41(10), 2004, e115.
17. Dobyns, W.B., Pagon, R.A., Armstrong, D., Curry, C.J., Greenberg, F., Grix, A., et al. Diagnostic criteria for Walker-Warburg syndrome. Am. J. Med. Genet 32:2 (1989), 195–210.
18. Dong, M., Noguchi, S., Endo, Y., Hayashi, Y.K., Yoshida, S., Nonaka, I., et al. DAG1 mutations associated with asymptomatic hyperCKemia and hypoglycosylation of alpha-dystroglycan. Neurology 84:3 (2015), 273–279.
19. Endo, T., Glycobiology of alpha-dystroglycan and muscular dystrophy. J. Biochem 157:1 (2015), 1–12.
20. Ervasti, J.M., Campbell, K.P., A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol 122:4 (1993), 809–823.
21. Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M.G., Campbell, K.P., Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345:6273 (1990), 315–319.
22. Fukuyama, Y., Osawa, M., Suzuki, H., Congenital progressive muscular dystrophy of the Fukuyama type – clinical, genetic and pathological considerations. Brain Dev 3:1 (1981), 1–29.
23. Geis, T., Marquard, K., Rodl, T., Reihle, C., Schirmer, S., von Kalle, T., et al. Homozygous dystroglycan mutation associated with a novel muscle-eye-brain disease-like phenotype with multicystic leucodystrophy. Neurogenetics 14:3–4 (2013), 205–213.
24. Godfrey, C., Clement, E., Mein, R., Brockington, M., Smith, J., Talim, B., et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 130:Pt 10 (2007), 2725–2735.
25. Godfrey, C., Foley, A.R., Clement, E., Muntoni, F., Dystroglycanopathies: coming into focus. Curr. Opin. Genet. Dev 21:3 (2011), 278–285.
26. Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med 364:16 (2011), 1513–1522.
27. Goyenvalle, A., Griffith, G., Babbs, A., El Andaloussi, S., Ezzat, K., Avril, A., et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med 21:3 (2015), 270–275.
28. Han, R., Kanagawa, M., Yoshida-Moriguchi, T., Rader, E.P., Ng, R.A., Michele, D.E., et al. Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of alpha-dystroglycan. Proc. Natl. Acad. Sci. U.S.A. 106:31 (2009), 12573–12579.
29. Hara, Y., Campbell, K.P., Dystroglycan: extracellular matrix receptor that links to cytoskeleton. Taniguchi, N., Endo, T., Hart, G.W., Seeberger, P.H., Wong, C., (eds.) Glycoscience: Biology and Medicine, 2015, Springer Japan, 1245–1251.
30. Hara, Y., Balci-Hayta, B., Yoshida-Moriguchi, T., Kanagawa, M., Beltran-Valero de Bernabe, D., Gundesli, H., et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med 364:10 (2011), 939–946.
31. Hayashi, Y.K., Ogawa, M., Tagawa, K., Noguchi, S., Ishihara, T., Nonaka, I., et al. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 57:1 (2001), 115–121.
32. Henry, M.D., Campbell, K.P., A role for dystroglycan in basement membrane assembly. Cell 95:6 (1998), 859–870.
33. Henry, M.D., Williamson, R.A., Campbell, K.P., Analysis of the role of dystroglycan in early postimplantation mouse development. Ann. N. Y. Acad. Sci 857 (1998), 256–259.
34. Ibraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., Slaughter, C.A., Sernett, S.W., Campbell, K.P., Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355:6362 (1992), 696–702.
35. Inamori, K., Endo, T., Gu, J., Matsuo, I., Ito, Y., Fujii, S., et al. N-Acetylglucosaminyltransferase IX acts on the GlcNAc beta 1,2-Man alpha 1-Ser/Thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan. J. Biol. Chem 279:4 (2004), 2337–2340.
36. Inamori, K., Yoshida-Moriguchi, T., Hara, Y., Anderson, M.E., Yu, L., Campbell, K.P., Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 335:6064 (2012), 93–96.
37. Ishigaki, K., Fukuyama type congenital muscular dystrophy. Takeda, S., Miyagoe-Suzuki, Y., Mori-Yoshimura, M., (eds.) Translational Research in Muscular Dystrophy, 2016, Springer Japan, 1–19.
38. Kanagawa, M., Toda, T., α-Dystroglycanopathy. Takeda, S., Miyagoe-Suzuki, Y., Mori-Yoshimura, M., (eds.) Translational Research in Muscular Dystrophy, first ed., 2016, Springer Japan, 21–38.
39. Kanagawa, M., Yu, C.C., Ito, C., Fukada, S., Hozoji-Inada, M., Chiyo, T., et al. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Hum. Mol. Genet 22:15 (2013), 3003–3015.
40. Kanagawa, M., Kobayashi, K., Tajiri, M., Manya, H., Kuga, A., Yamaguchi, Y., et al. Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy. Cell Rep 14:9 (2016), 2209–2223.
41. Kobayashi, K., Nakahori, Y., Miyake, M., Matsumura, K., Kondo-Iida, E., Nomura, Y., et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394:6691 (1998), 388–392.
42. Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C., Kunkel, L.M., Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:3 (1987), 509–517.
43. Lefeber, D.J., Schonberger, J., Morava, E., Guillard, M., Huyben, K.M., Verrijp, K., et al. Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am. J. Hum. Genet 85:1 (2009), 76–86.
44. Leung, D.G., Wagner, K.R., Therapeutic advances in muscular dystrophy. Ann. Neurol 74:3 (2013), 404–411.
45. Longman, C., Brockington, M., Torelli, S., Jimenez-Mallebrera, C., Kennedy, C., Khalil, N., et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum. Mol. Genet 12:21 (2003), 2853–2861.
46. Lu, Q.L., Cirak, S., Partridge, T., What can we learn from clinical trials of exon skipping for DMD? Molecular therapy. Nucleic Acids, 3, 2014, e152.
47. Manzini, M.C., Tambunan, D.E., Hill, R.S., Yu, T.W., Maynard, T.M., Heinzen, E.L., et al. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am. J. Hum. Genet 91:3 (2012), 541–547.
48. Manzur, A.Y., Kuntzer, T., Pike, M., Swan, A., Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev(1), 2008 CD003725.
49. Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., Manzur, A.Y., Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev(5), 2016 CD003725.
50. Meilleur, K.G., Zukosky, K., Medne, L., Fequiere, P., Powell-Hamilton, N., Winder, T.L., et al. Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutations. J. Neuropathol. Exp. Neurol 73:5 (2014), 425–441.
51. Mendell, J.R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., et al. Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med 363:15 (2010), 1429–1437.
52. Mercuri, E., Muntoni, F., Muscular dystrophies. Lancet 381:9869 (2013), 845–860.
53. Messina, S., Tortorella, G., Concolino, D., Spano, M., D'Amico, A., Bruno, C., et al. Congenital muscular dystrophy with defective alpha-dystroglycan, cerebellar hypoplasia, and epilepsy. Neurology 73:19 (2009), 1599–1601.
54. Michele, D.E., Campbell, K.P., Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J. Biol. Chem 278:18 (2003), 15457–15460.
55. Michele, D.E., Barresi, R., Kanagawa, M., Saito, F., Cohn, R.D., Satz, J.S., et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418:6896 (2002), 417–422.
56. Moore, S.A., Saito, F., Chen, J., Michele, D.E., Henry, M.D., Messing, A., et al. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418:6896 (2002), 422–425.
57. Murakami, N., Hayashi, Y.K., Oto, Y., Shiraishi, M., Itabashi, H., Kudo, K., et al. Congenital generalized lipodystrophy type 4 with muscular dystrophy: clinical and pathological manifestations in early childhood. Neuromuscul. Disord 23:5 (2013), 441–444.
58. Murakami, T., Hayashi, Y.K., Noguchi, S., Ogawa, M., Nonaka, I., Tanabe, Y., et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann. Neurol 60:5 (2006), 597–602.
59. Murakami, T., Ishigaki, K., Shirakawa, S., Ikenaka, H., Sakauchi, M., Osawa, M., Severe muscle damage following viral infection in patients with Fukuyama congenital muscular dystrophy. Brain Dev 34:4 (2012), 293–297.
60. Nowak, K.J., Davies, K.E., Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5:9 (2004), 872–876.
61. Okada, T., Takeda, S., Current challenges and future directions in recombinant AAV-mediated gene therapy of Duchenne muscular dystrophy. Pharmaceuticals (Basel) 6:7 (2013), 813–836.
62. Ozawa, E., Yoshida, M., Suzuki, A., Mizuno, Y., Hagiwara, Y., Noguchi, S., Dystrophin-associated proteins in muscular dystrophy. Hum. Mol. Genet 4 (1995), 1711–1716 Spec No.
63. Pasquini, F., Guerin, C., Blake, D., Davies, K., Karpati, G., Holland, P., The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscul. Disord 5:2 (1995), 105–114.
64. Praissman, J.L., Live, D.H., Wang, S., Ramiah, A., Chinoy, Z.S., Boons, G.J., et al. B4GAT1 is the priming enzyme for the LARGE-dependent functional glycosylation of alpha-dystroglycan. Elife, 3, 2014.
65. Praissman, J.L., Willer, T., Sheikh, M.O., Toi, A., Chitayat, D., Lin, Y.Y., et al. The functional O-mannose glycan on alpha-dystroglycan contains a phospho-ribitol primed for matriglycan addition. Elife, 5, 2016.
66. Riemersma, M., Mandel, H., van Beusekom, E., Gazzoli, I., Roscioli, T., Eran, A., et al. Absence of alpha- and beta-dystroglycan is associated with Walker-Warburg syndrome. Neurology 84:21 (2015), 2177–2182.
67. Rifai, Z., Welle, S., Moxley, R.T. 3rd, Lorenson, M., Griggs, R.C., Effect of prednisone on protein metabolism in Duchenne dystrophy. Am. J. Physiol 268:1 Pt 1 (1995), E67–E74.
68. Rodino-Klapac, L.R., Montgomery, C.L., Bremer, W.G., Shontz, K.M., Malik, V., Davis, N., et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther 18:1 (2010), 109–117.
69. Saito, F., Moore, S.A., Barresi, R., Henry, M.D., Messing, A., Ross-Barta, S.E., et al. Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. Neuron 38:5 (2003), 747–758.
70. Saito, F., Kanagawa, M., Ikeda, M., Hagiwara, H., Masaki, T., Ohkuma, H., et al. Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice. Hum. Mol. Genet 23:17 (2014), 4543–4558.
71. Santavuori, P., Pihko, H., Sainio, K., Lappi, M., Somer, H., Haltia, M., et al. Muscle-eye-brain disease and Walker-Warburg syndrome. Am. J. Med. Genet 36:3 (1990), 371–374.
72. Santavuori, P., Valanne, L., Autti, T., Haltia, M., Pihko, H., Sainio, K., Muscle-eye-brain disease: clinical features, visual evoked potentials and brain imaging in 20 patients. Eur. J. Paediatr. Neurol 2:1 (1998), 41–47.
73. Sato, S., Omori, Y., Katoh, K., Kondo, M., Kanagawa, M., Miyata, K., et al. Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat. Neurosci 11:8 (2008), 923–931.
74. Sklar, R.M., Brown, R.H. Jr., Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro. J. Neurol. Sci 101:1 (1991), 73–81.
75. Spuler, S., Engel, A.G., Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology 50:1 (1998), 41–46.
76. Stevens, E., Carss, K.J., Cirak, S., Foley, A.R., Torelli, S., Willer, T., et al. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of alpha-dystroglycan. Am. J. Hum. Genet 92:3 (2013), 354–365.
77. Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K., Sudhof, T.C., A stoichiometric complex of neurexins and dystroglycan in brain. J. Cell Biol 154:2 (2001), 435–445.
78. Takeda, S., Kondo, M., Sasaki, J., Kurahashi, H., Kano, H., Arai, K., et al. Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. Hum. Mol. Genet 12:12 (2003), 1449–1459.
79. Talts, J.F., Andac, Z., Gohring, W., Brancaccio, A., Timpl, R., Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J. 18:4 (1999), 863–870.
80. Tang, G., Yue, Z., Talloczy, Z., Hagemann, T., Cho, W., Messing, A., et al. Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways. Hum. Mol. Genet 17:11 (2008), 1540–1555.
81. Taniguchi-Ikeda, M., Kobayashi, K., Kanagawa, M., Yu, C.C., Mori, K., Oda, T., et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478:7367 (2011), 127–131.
82. Toda, T., Kobayashi, K., Takeda, S., Sasaki, J., Kurahashi, H., Kano, H., et al. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy. Congenit. Anom. (Kyoto) 43:2 (2003), 97–104.
83. van Deutekom, J.C., Bremmer-Bout, M., Janson, A.A., Ginjaar, I.B., Baas, F., den Dunnen, J.T., et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet 10:15 (2001), 1547–1554.
84. van Reeuwijk, J., Brunner, H.G., van Bokhoven, H., Glyc-O-genetics of Walker-Warburg syndrome. Clin. Genet 67:4 (2005), 281–289.
85. Vajsar, J., Schachter, H., Walker-Warburg syndrome. Orphanet J. Rare Dis, 1, 2006, 29.
86. Vannoy, C.H., Xu, L., Keramaris, E., Lu, P., Xiao, X., Lu, Q.L., Adeno-associated virus-mediated overexpression of LARGE rescues alpha-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein. Hum. Gene Ther. Methods 25:3 (2014), 187–196.
87. Walker, E., Lissencephaly. Arch. Neuro. Psychiatr 48:1 (1942), 13–29.
88. Warburg, M., Hydrocephaly, congenital retinal nonattachment, and congenital falciform fold. Am. J. Ophthalmol 85:1 (1978), 88–94.
89. Whitmore, C., Fernandez-Fuente, M., Booler, H., Parr, C., Kavishwar, M., Ashraf, A., et al. The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice. Hum. Mol. Genet 23:7 (2014), 1842–1855.
90. Willer, T., Lee, H., Lommel, M., Yoshida-Moriguchi, T., de Bernabe, D.B., Venzke, D., et al. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat. Genet 44:5 (2012), 575–580.
91. Willer, T., Inamori, K., Venzke, D., Harvey, C., Morgensen, G., Hara, Y., et al. The glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated alpha-dystroglycan functional glycosylation. Elife, 3, 2014.
92. Wright, K.M., Lyon, K.A., Leung, H., Leahy, D.J., Ma, L., Ginty, D.D., Dystroglycan organizes axon guidance cue localization and axonal pathfinding. Neuron 76:5 (2012), 931–944.
93. Xu, L., Lu, P.J., Wang, C.H., Keramaris, E., Qiao, C., Xiao, B., et al. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of alpha-dystroglycan and improves muscle functions. Mol. Ther 21:10 (2013), 1832–1840.
94. Yang, A.C., Ng, B.G., Moore, S.A., Rush, J., Waechter, C.J., Raymond, K.M., et al. Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy. Mol. Genet. Metab 110:3 (2013), 345–351.
95. Yoshida, A., Kobayashi, K., Manya, H., Taniguchi, K., Kano, H., Mizuno, M., et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1:5 (2001), 717–724.
96. Yoshida-Moriguchi, T., Campbell, K.P., Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 25:7 (2015), 702–713.
97. Yoshida-Moriguchi, T., Yu, L., Stalnaker, S.H., Davis, S., Kunz, S., Madson, M., et al. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 327:5961 (2010), 88–92.
98. Yoshida-Moriguchi, T., Willer, T., Anderson, M.E., Venzke, D., Whyte, T., Muntoni, F., et al. SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 341:6148 (2013), 896–899.
99. Yu, M., He, Y., Wang, K., Zhang, P., Zhang, S., Hu, H., Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Hum. Gene Ther 24:3 (2013), 317–330.